In Veritas Makes Key Patent Filing in Labour Prediction

Market Wire, June, 2006

IVMD Inc. (OTCBB: IVME), a novel medical device company, today announced that it filed the 4th patent around its pregnancy prediction technology.

Post trial analysis of data obtained during initial clinical trials of the unique POLO (Predictor Of Labour Onset) device from In Veritas Medical Diagnostics (IVMD) has yielded exciting new results.

Over 160GB of data were collected during the 8-month trial during which expectant mothers self monitored in their own homes daily from 30 weeks of pregnancy, with MHRA approved equipment. Believed to be the first study of its kind, it has clearly demonstrated the potential of this novel device in the antenatal care sector. The latest analysis has shown that POLO can detect two separate events that together accurately predict the onset of labour; the first event gives a preliminary warning at approximately two weeks before onset, with a second warning 3 - 5 days before labour begins.

The detection of this 'second warning' has significantly increased the potential usefulness of the device and has led IVMD to file the 4th patent to protect this technology. The company is now keen to develop POLO and is actively seeking commercial partners to collaborate with the next phase of clinical trials and develop the product for market.

Designed for home use, POLO introduces significant social and medical benefits potentially allowing early intervention in cases of premature labour. Over 10% of births are currently pre-term, i.e. occur before 37 weeks gestation, with very serious medical and economic implications.

POLO is non-invasive and only requires the pregnant mother to attach a sensor to her abdomen for less than 10 minutes each day. The device monitors complex electrical signals in the uterus, thought to relate to cell bridging, that change as the body transmits instructions to co-ordinate the muscle contractions of labour. IVMD has mapped two distinct changes in the energy pattern, detecting bursts of activity that provide a positive and accurate indicator of labour long before the mother is aware of any physical signs.

John Fuller, President and CEO, said, "This analysis both confirms the basis for our science, and exceeds the tough design specification that we set ourselves. Market research had identified a market for a product with a 3 to 5 day prediction capability, and we now know we can address that market. Not only is this a lifestyle product, but its application in assessing at-risk mothers could save significant healthcare costs and improve the long-term outcomes for both mother and baby. This trial completion and new protection paves the way for a commercial application in 2007."

About IVMD, Inc.

IVMD uses its proven, patented core technology to design, develop and test medical devices for near patient testing and monitoring.

Our products serve large global markets in the monitoring of chronic conditions affecting large numbers of the population. Two applications form the focus of current development work. The first is a device for measuring the coagulation of blood in patients with cardiovascular disorders which is in the last stages of clinical trials. The second a device that predicts the onset of human labour up to several weeks before birth.

Our scientists are currently working on several exciting minimally and non-invasive additional products based on novel, highly sensitive immunoassays. From across all sectors of industry, our development team use our technology to create rapid prototype and product development, in partnership with major marketing and distribution partners.

IVMD actively seek bespoke product development, manufacturing, marketing and distribution agreements.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe,'' "expects,'' "projects,'' "forecasts,'' "intends,'' "will,'' "anticipated,'' "could,'' or "may,'' and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

Contact: IVMD (UK) Ltd. In the UK info@ivmd.com